Kiniksa Pharmaceuticals, Ltd.
KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatoā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$40.32
Price+0.08%
$0.03
1Y
Price
Market Cap
$2.955b
Mid
Price/Earnings 3y Avg5y Avg
89.6x
Premium
Premium
Financials Overview
Key metrics over the past few years+12.9%
EBITDA Margin+11.4%
Net Profit Margin+17.8%
Free Cash Flow MarginRevenue
$529.332m
+25.1%
1y CAGR+34.8%
3y CAGR+143.9%
5y CAGREarnings
$4.790m
+111.1%
1y CAGR-129.3%
3y CAGR-42.9%
5y CAGREPS
$0.04
+106.7%
1y CAGR-128.5%
3y CAGR-43.1%
5y CAGRBook Value
$495.007m
$661.150m
Assets$166.143m
Liabilities$9.765m
DebtDebt to Assets
1.5%
1.7x
Debt to EBITDAFree Cash Flow
$66.491m
+161.7%
1y CAGR+128.5%
3y CAGR+122.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company